Class B Scavenger Receptor CD36 as a Potential Therapeutic Target in Inflammation Induced by Danger-Associated Molecular Patterns
The class B scavenger receptor CD36 is known to bind and mediate the transport of lipid-related ligands and it functions as a pattern recognition receptor (PRR) for a variety of pathogens, including bacteria and viruses. In this study, we assessed CD36's role as a PRR mediating pro-inflammatory effects of several known Danger-Associated Molecular Patterns (DAMPs) used either as a single preparation or as a combination of DAMPs in the form of total cell/skeletal muscle tissue lysates. Our data demonstrated that multiple DAMPs, including HMGB1, HSPs, histone H3, SAA, and oxPAPC, as well as cell/tissue lysate preparations, induced substantially higher (~7-10-fold) IL-8 cytokine responses in HEK293 cells overexpressing CD36 compared to control WT cells. At the same time, DAMP-induced secretion of IL-6 in bone marrow-derived macrophages (BMDM) from CD36-/- mice was markedly (~2-3 times) reduced, as compared to macrophages from normal mice. Synthetic amphipathic helical peptides (SAHPs), known CD36 ligands, efficiently blocked CD36-dependent inflammatory responses induced by both cell and tissue lysates, HMGB1 and histone H3 in CD36+ cells. IP injection of total cellular lysate preparation induced inflammatory responses that were assessed by the expression of liver and lung pro-inflammatory markers, including IL-6, TNF-α, CD68, and CXCL1, and was reduced by ~50% in CD36-deficient mice compared to normal mice. Our findings demonstrate that CD36 is a PRR contributing to the innate immune response via mediating DAMP-induced inflammatory signaling and highlight the importance of this receptor as a potential therapeutic target in DAMP-associated inflammatory conditions.
Authors
- Robert A. Star (ORCID: https://orcid.org/0000-0003-0940-3079)
- Peter S.T. Yuen (ORCID: https://orcid.org/0000-0001-9557-3909)
- Konstantin G. Birukov (ORCID: https://orcid.org/0000-0002-0303-5394)
- Tatyana G. Vishnyakova
- Anna A. Birukova (ORCID: https://orcid.org/0000-0003-0535-7693)
- Yunbo Ke (ORCID: https://orcid.org/0000-0002-4151-9058)
- Alexander V. Bocharov (ORCID: https://orcid.org/0000-0002-3482-2980)
- Irina N. Baranova (ORCID: https://orcid.org/0000-0003-4250-1340)
- Zhigang Chen (ORCID: https://orcid.org/0000-0002-0797-7215)
- Takayuki Tsuji (ORCID: https://orcid.org/0000-0003-3120-5562)
- Thomas L. Eggerman
- Amy P. Patterson
Institutions
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Office of the Director (US)
- Division of Program Coordination Planning and Strategic Initiatives (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- Cells
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3390/cells13231992
- Citations
- 8
- Primary Topic
- Advanced Glycation End Products research
- Type
- article
- Field-Weighted Citation Impact
- 3.05
Funders
- National Institutes of Health
- NIH Clinical Center